Here is how UnitedHealth Group (UNH) and Alto Neuroscience, Inc. (ANRO) have performed compared to their sector so far this year.
Alto Neuroscience has seen its share price move sharply over the past year, which puts a spotlight on whether that market value lines up with the strength of its balance sheet. With the stock now well above levels seen earlier in the year, investors are asking how much of that shift is supported by the company’s book value. The share price has returned 118.2% over the past year, which raises the question of how firmly that move is anchored in Alto Neuroscience’s underlying net assets. The...
MOUNTAIN VIEW, Calif., November 03, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:
Find out all the key statistics for Alto Neuroscience Inc (ANRO-N), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.
Dividend history for Alto Neuroscience Inc (ANRO-N) yield, ex-date and other distribution information to help income investors find and manage investments.
The latest insider stock transactions for Alto Neuroscience Inc (ANRO).
Detailed price information for Alto Neuroscience Inc (ANRO-N) from The Globe and Mail including charting and trades.
MOUNTAIN VIEW, Calif., September 09, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:
MOUNTAIN VIEW, Calif., August 27, 2026--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026.
This is the newest page. Registered accounts read further back.